Wajd Alkabbani

Wajd Alkabbani

Auto-generated profile, based on publicly available information

Wajd Alkabbani

School of Pharmacy University of Waterloo Waterloo Ontario Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2024 in BMJ
Verified
Journal Article
Open access
PDF file
WAWajd Alkabbani
Wajd Alkabbani
KSKarine Suissa
Karine Suissa
KGKristine D Gu
Kristine D Gu
SCSara J Cromer
Sara J Cromer
JPJulie M Paik
Julie M Paik
EPElisabetta Patorno
Elisabetta Patorno
Objective To assess whether use of glucagon-like peptide-1 (GLP-1) receptor agonists before upper gastrointestinal endoscopy is associated with increased risk of pulmonary aspiration or discontinuation of the procedure compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Design Cohort study. Setting Two deidentified US commercial healthcare databases. Participants 43 365 adults (≥18 years) with type 2 diabetes who used a GLP-1 receptor agonist or SGLT-2 inhibitor within 30 days before upper gastrointestinal endoscopy. Main outcome measures The primary outcome was pulmonary aspiration on the day of or the day after endoscopy, defined using diagnostic codes. The secondary outcome was discontinuation of endoscopy. Risk ratios and corresponding 95% confidence intervals (CIs) were estimated after fine stratification weighting based on propensity score. Results After weighting, 24 817 adults used a GLP-1 receptor agonist (mean age 59.9 years; 63.6% female) and 18 537 used an SGLT-2 inhibitor (59.8 years; 63.7% female). Among users of GLP-1 receptor agonists and SGLT-2 inhibitors, the weighted risk per 1000 people was, respectively, 4.15 and 4.26 for pulmonary aspiration and 9.79 and 4.91 for discontinuation of endoscopy. Compared with SGLT-2 inhibitor use, GLP-1 receptor agonist use was not associated with an increased risk of pulmonary aspiration (pooled risk ratio 0.98, 95% CI 0.73 to 1.31), although it was associated with a higher risk for discontinuation of endoscopy (1.99, 1.56 to 2.53). Conclusions In this comparative cohort study, no increased risk of pulmonary aspiration during upper gastrointestinal endoscopy was observed among adults with type 2 diabetes using GLP-1 receptor agonists compared with SGLT-2 inhibitors within 30 days of the procedure; however, GLP-1 receptor agonists were associated with a higher risk of discontinuation of endoscopy, possibly owing to a higher risk of retained gastric content. In the absence of evidence from randomized trials, these findings could inform future practice recommendations on the preprocedural protocol for patients requiring endoscopy.


1 June 2022 in Canadian Journal of Diabetes
Verified
Journal Article
Open access
WAWajd Alkabbani
Wajd Alkabbani
AZArsène Zongo
Arsène Zongo
JMJasjeet K. Minhas-Sandhu
Jasjeet K. Minhas-Sandhu
DEDean T. Eurich
Dean T. Eurich
BSBaiju R. Shah
Baiju R. Shah
JGJM Gamble
JM Gamble
Sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced glycosuria is hypothesized to increase the risk of urinary tract infections (UTIs). We assessed the risk of UTIs associated with SGLT2 inhibitor initiation in type 2 diabetes. We conducted a population-based cohort study using primary care data from the United Kingdom's Clinical Practice Research Datalink (CPRD) and administrative health-care data from Alberta, Canada. From a base cohort of new metformin users, we constructed 5 comparative cohorts, wherein the exposure contrast was defined as new use of SGLT2 inhibitors or 1 of 5 active comparators: dipeptidylpeptidase-4 (DPP-4) inhibitors, sulfonylureas (SU), glucagon-like peptide-1 receptor agonists (GLP-1 RA), thiazolidinediones (TZD) and insulin. We defined a composite UTI outcome based on hospitalizations or physician visit records. For each comparative cohort, we used high-dimensional propensity score matching to adjust for confounding and Cox proportional hazards regression to estimate the hazard ratios (HRs) in each database. We meta-analyzed estimates using a random-effects model. SGLT2 inhibitor use was not associated with a higher risk of UTI compared with DPP-4 inhibitors (pooled HR, 1.08; 95% confidence interval [CI], 0.89 to 1.30), SU (pooled HR, 1.08; 95% CI, 0.90 to 1.30), GLP-1 RA (pooled HR, 0.81; 95% CI, 0.61 to 1.09) or TZD (pooled HR, 0.81; 95% CI, 0.55 to 1.19). The risk of UTI was lower compared with insulin (pooled HR, 0.74; 95% CI, 0.63 to 0.87). The risk of UTI did not differ based on the SGLT2 inhibitor agent or dose. Last, SGLT2 inhibitor initiation was not associated with an increased risk of UTI recurrence. SGLT2 inhibitor use is not associated with an increased risk of UTIs, compared with other antidiabetic agents.

14 December 2022 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
WAWajd Alkabbani
Wajd Alkabbani
CMColleen J. Maxwell
Colleen J. Maxwell
RMRuth Ann Marrie
Ruth Ann Marrie
STSuzanne L. Tyas
Suzanne L. Tyas
ILIliana C. Lega
Iliana C. Lega
JGJM Gamble
JM Gamble
OBJECTIVE: Severe hypoglycemia is associated with an increased risk of dementia. We examined if the association is consistently present in mid- and late-life hypoglycemia. RESEARCH DESIGN AND METHODS: Using health care data from Population Data BC, we created a base cohort of patients age ≥40 years with incident type 2 diabetes. Exposure was the first occurrence of severe hypoglycemia (hospitalization or physician visit). We assessed exposure versus no exposure in mid- (age 45–64 years) and late-life (age 65–84 years) cohorts. Index date was the later of the 45th birthday (midlife cohort), 65th birthday (late-life cohort), or diabetes diagnosis. Those with hypoglycemia or dementia before the index date were excluded. Patients were followed from index date until dementia diagnosis, death, emigration, or 31 December 2018. Exposure was modeled as time dependent. We adjusted for confounding using propensity score weighting. Dementia risk was estimated using cause-specific hazards models with death as a competing risk. RESULTS: Of 221,683 patients in the midlife cohort, 1,793 experienced their first severe hypoglycemic event. Over a median of 9.14 years, 3,117 dementia outcomes occurred (32 among exposed). Of 223,940 patients in the late-life cohort, 2,466 experienced their first severe hypoglycemic event. Over a median of 6.7 years, 15,997 dementia outcomes occurred (158 among exposed). The rate of dementia was higher for those with (vs. without) hypoglycemia in both the mid- (hazard ratio 2.85; 95% CI 1.72–4.72) and late-life (2.38; 1.83–3.11) cohorts. CONCLUSIONS: Both mid- and late-life hypoglycemia were associated with approximately double the risk of dementia, indicating the need for prevention throughout the life course of those with diabetes.

20 May 2020 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
PDF file
RPRyan Pelletier
Ryan Pelletier
KNKelvin Ng
Kelvin Ng
WAWajd Alkabbani
Wajd Alkabbani
YLYoussef Labib
Youssef Labib
NMNicolas Mourad
Nicolas Mourad
JGJM Gamble
JM Gamble
Aims: To summarize reported cancer events associated with SGLT‐2 inhibitors used in patients with type 2 diabetes mellitus, as well as assess the quality of included reviews.Materials and methods: In May 2019, we searched PubMed, Embase and the Cochrane Library for quantitative systematic reviews assessing the safety of SGLT‐2 inhibitors. Data were abstracted using a standardized form, and methodological quality was assessed using the AMSTAR 2 tool. Main outcome measures included total cancer events and specific cancers such as breast cancer, bladder cancer, gastrointestinal cancer, prostate cancer, respiratory cancer, renal cancer and skin cancer. Pooled treatment effects from included reviews were summarized for SGLT‐2 inhibitors as a class and for individual SGLT‐2 inhibitors commonly used worldwide (canagliflozin, dapagliflozin and empagliflozin).Results: We screened 1248 unique citations, of which eight quantitative systematic reviews meta‐analysed results from studies reporting the association between an SGLT‐2 inhibitor and any cancer. Only one review was rated as high quality according to AMSTAR 2 assessment. In total, data from 170 cancer‐related point estimates (PE) were reported. As a class, SGLT‐2 inhibitors were not associated with an increased risk of any cancer event versus placebo and active comparators. Most point estimates (7/143) were nonsignificant for individual cancers except for two associations. Empagliflozin was associated with an increased risk of bladder cancer versus placebo and active comparators in two reviews, while canagliflozin appeared protective for gastrointestinal cancer versus placebo and active comparators in one review.Conclusions: It appears that SGLT‐2 inhibitors are not associated with an increased risk of total cancer or specific cancers in patients with type 2 diabetes. However, higher quality evidence is needed to derive confident conclusions.

4 April 2018 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
JBJaden Brandt
Jaden Brandt
WAWajd Alkabanni
Wajd Alkabanni
SASilvia Alessi-Severini
Silvia Alessi-Severini
CLChristine Leong
Christine Leong